ArticleThoracic cancer2022

Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.

Jehun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.